Extract
“Cytokine storm”, inflammation-mediated severe lung damage and defective haemostasis are the main underlying reasons for morbidity and mortality in coronavirus disease 2019 (COVID-19) patients [1]. Several immunotherapies that target various inflammatory processes have been successfully used in COVID-19 patients and many other strategies are under evaluation [2, 3]. However, in view of dysregulated immune responses in severe COVID-19 patients, we suggest that CD4+CD25+FoxP3+ regulatory T-cell (Treg)-based strategies could be considered for patient management.
Abstract
In view of dysregulated immune response, “cytokine storm” and inflammation-induced lung damage in severely ill COVID-19 patients, we propose that CD4+CD25+FoxP3+ regulatory T-cell-based therapies could be considered for patient management https://bit.ly/3eKqWPo
Footnotes
Conflict of interest: E. Stephen-Victor has nothing to disclose.
Conflict of interest: M. Das has nothing to disclose.
Conflict of interest: A. Karnam has nothing to disclose.
Conflict of interest: B. Pitard has nothing to disclose.
Conflict of interest: J-F. Gautier has nothing to disclose.
Conflict of interest: J. Bayry reports grants from Agence Nationale de la Recherche, France (Appel Flash COVID-19-COVIMUNE and ANR-19-CE17-0021(BASIN)), outside the submitted work.
Support statement: Partly supported by grants from Agence Nationale de la Recherche, France (Appel Flash COVID-19-COVIMUNE and ANR-19-CE17-0021(BASIN)). Funding information for this article has been deposited with the Crossref Funder Registry.
- Received June 5, 2020.
- Accepted June 23, 2020.
- Copyright ©ERS 2020.
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.